A ureteral stent is provided. The stent may include a first section having a first wall defining a first luminal section. The stent may further include a second section having a second wall defining a second luminal section. The second section can be enabled to substantially close at times external pressure is applied to the stent.

A percutaneous urinary catheter configured to be deployed in a urinary tract, including: (a) a proximal portion; and (b) a distal portion including a retention portion configured to be deployed in a kidney and/or a renal pelvis, the retention portion including one or more drainage holes leading to one or more lumen(s) within the proximal portion, wherein the retention portion, when deployed, defines a three-dimensional shape sized and positioned to maintain patency of fluid flow between the kidney and/or renal pelvis and a proximal end of the catheter by inhibiting mucosal tissue from appreciably occluding the one or more drainage holes when negative pressure is applied through the catheter.

The present invention relates to a catheter 10. The catheter 10 includes a catheter tube 12 having a tip end 13 and a distal end 14, with the distal end 14 being coupled to or forming at least part of a funnel 16 for discharging fluid from within the catheter tube 12. A sleeve 18 is provided about the catheter tube 12 which is coupled at an end thereof to the funnel 16 and extends towards the tip end 13 of the catheter tube 12. The catheter 10 additionally includes a wetting mechanism 20 which is integrally formed with the funnel 16 and includes a holding chamber 22 and a fluid outlet 26 operable to allow fluid 24 from within the holding chamber 22 to be released within the sleeve 18 for wetting an outer surface of the catheter tube 12.

Various embodiments disclosed relate to drug-coated balloon catheters for treating, preventing, or reducing the recurrence of a stricture and/or cancer, or for treating benign prostatic hyperplasia (BPH), in a non-vascular body lumen and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent. In some embodiments, the balloon catheter includes a length-control mechanism which stretches and elongates the balloon when it is in a deflated state, giving the balloon a smaller cross-sectional deflated profile for tracking through the body lumen and for removal after treatment.

A closed-loop home diuretic therapy system includes a monitoring device attached to the patient, the device having a sensor to detect a wall of a bladder, an accelerometer to detect an orientation of device to account for bladder positions, and a processor to determine an amount of urine in the bladder based on the detected wall and the orientation and calculate urine output volume based on the determined amount of urine, and a diuretic administration device configured to communicate with the monitoring device, the In administration device having a subcutaneous injection site, a diuretic delivery and storage device to deliver diuretic stored therein to the injection site, and a control circuit configured to regulate the volume and rate of diuretic delivered from the storage device to the injection site based on the calculated urine output volume and a target volume and rate of diuretic.

A pump assembly is provided, including a pump module configured to be positioned within an interior portion of a ureter and/or renal pelvis of a patient for providing negative pressure to the patient's ureter and/or kidney, the pump module including: a housing including a flow channel for conducting fluid, wherein the housing is configured to be positioned within the interior portion of the ureter and/the renal pelvis; and a pump element positioned within the channel to draw fluid through the channel; and a control module coupled to the pump module, the control module being configured to direct motion of the pump element to control flow rate of fluid passing through the channel, and including a housing configured to be positioned within at least one of a second interior portion of the patient's ureter, a second portion of the patient's renal pelvis, or an interior portion of a patient's bladder.

Provided is an antireflux ureteral stent, including: a hollow tube-shaped stent body inserted into the ureter to guide urine from the kidneys to the bladder and provided with a flow path for flow of the urine thereinside; and an extratube backflow prevention mechanism provided in an umbrella shape, made of a flexible material, on an outer side surface of the stent body to be unfolded or folded along a flow direction of the urine and configured to prevent backflow of the urine while being unfolded by flow pressure of the urine when the urine backflows along an extratube gap formed between the stent body and the ureter, wherein the extratube backflow prevention mechanism is formed in a star-shaped cross-section with a plurality of vertices centered on the stent body and provided with a star-shaped cross section that expands toward the bladder along a longitudinal direction of the stent body.

Ureteral catheters and assemblies are provided including: a proximal portion; and a distal portion, the distal portion including a retention portion, wherein the retention portion includes an inwardly facing side including one or more drainage ports and an outwardly facing side, and wherein, when negative pressure is applied through the ureteral catheter, fluid is drawn into the ureteral catheter through the one or more drainage ports while mucosal tissue is prevented from appreciably occluding the one or more drainage ports.

A Direct Sodium Removal method, apparatus and solution for treating patients in heart failure, and having a glomerular filtration rate greater than 15 mL/min/1.73 m.sup.2, or residual kidney function corresponding to normal to CKD Stage 4, is provided in which a no or low sodium DSR infusate is administered to the peritoneal cavity for a predetermined dwell period and then removed, thereby removing sodium from the body. The resulting elimination of fluid from the patient by i) functioning of the kidneys through urination and ii) direct removal of osmotic ultrafiltrate from the peritoneal cavity, restores serum sodium concentrations to healthy levels and thereby reduces fluid overload in the patient.

A Direct Sodium Removal method, apparatus and solution for treating patients in heart failure, and having a glomerular filtration rate greater than 15 mL/min/1.73 m.sup.2, or residual kidney function corresponding to normal to CKD Stage 4, is provided in which a no or low sodium DSR infusate is administered to the peritoneal cavity for a predetermined dwell period and then removed, thereby removing sodium from the body. The resulting elimination of fluid from the patient by i) functioning of the kidneys through urination and ii) direct removal of osmotic ultrafiltrate from the peritoneal cavity, restores serum sodium concentrations to healthy levels and thereby reduces fluid overload in the patient.